Pradžia › Dermatitas › Kalifornija
Dermatitas klinikiniai tyrimai Kalifornija
6 tyrimai dėl Dermatitas ieško dalyvių vietose Kalifornija.
Miestai Kalifornija
Oficialus tyrimo tekstas (anglų kalba)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fountain Valley
- Novartis Investigative Site, Los Angeles
- Novartis Investigative Site, Sacramento
- ir dar 2
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT06947993First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Alliance Clinical West Hills (Focus Clinical Research), West Hills
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07527923A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm, San Diego
Renkami dalyviai3 fazė
Amžius nuo 6 iki 11 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06807268A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Northridge Clinical Trials, Northridge
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT07765888A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Marvel Research, LLC, Huntington Beach
- Metropolis Dermatology, Los Angeles
- Dermatology Research Associates, Los Angeles
- ir dar 4
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-08-12 · NCT07037901Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.